• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative?

    Simply Wall St·08/09/2026 09:33:53
    Listen to the news
    • Alkermes plc recently reported past second-quarter 2026 results, with revenue rising to US$496.01 million while net income fell sharply to US$0.50 million, and the company issued guidance calling for third-quarter 2026 revenue of US$450 million to US$470 million alongside an expected full-year 2026 GAAP net loss of US$95 million to US$115 million.
    • At the same time, Alkermes paused buybacks after repurchasing 5.32% of its shares since 2024 and filed a US$311.11 million employee share plan shelf, moves that highlight a shift toward preserving cash and supporting equity-based compensation while the business operates at a loss.
    • We’ll now examine how Alkermes’ swing from prior profitability to an expected 2026 GAAP net loss reshapes its investment narrative.

    The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

    Alkermes Investment Narrative Recap

    To own Alkermes today, you need to believe that its central nervous system portfolio and orexin pipeline can justify current valuation even as the company moves back into losses. The latest update, with Q2 2026 profitability nearly vanishing and management guiding to a full year GAAP net loss, makes near term execution on R&D productivity and cost control the key catalyst while amplifying the risk that rising expenses outpace sustainable revenue.

    The most relevant recent move here is Alkermes’ decision to pause buybacks after retiring 5.32% of its shares and to register US$311.11 million of stock for an employee plan. In the context of an expected US$95 million to US$115 million GAAP loss in 2026, these actions intersect directly with the core catalyst of delivering on late stage orexin trials while heightening the risk that dilution and weaker earnings quality matter more to the equity story.

    Yet alongside the promise of orexin data, investors also need to be aware that rising R&D costs and one off items could make future profit trends look very different...

    Read the full narrative on Alkermes (it's free!)

    Alkermes' narrative projects $2.1 billion revenue and $264.8 million earnings by 2029. This implies 11.1% yearly revenue growth and a $112.1 million earnings increase from $152.7 million today.

    Uncover how Alkermes' forecasts yield a $47.69 fair value, a 3% downside to its current price.

    Exploring Other Perspectives

    ALKS 1-Year Stock Price Chart
    ALKS 1-Year Stock Price Chart

    Before this setback, the most optimistic analysts were assuming revenue would reach about US$2.8 billion and earnings roughly US$951 million by 2029, yet this new swing back to losses and heightened pricing and reimbursement risk shows just how far real world outcomes can deviate from even the rosiest projections.

    Explore 5 other fair value estimates on Alkermes - why the stock might be worth as much as 94% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.